About Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. It has have partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 different programs under license with it are in various stages of commercialization and development. Its partners have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease and kidney disease, among others. It is developing a small molecule glucagon receptor antagonist for the treatment of Type II diabetes mellitus.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: LGND
- CUSIP: 53220K50
- Previous Close: $100.38
- 50 Day Moving Average: $104.96
- 200 Day Moving Average: $104.58
- 52-Week Range: $20,898,000.00 - $87.50
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 23.29
- P/E Growth: 0.84
- Market Cap: $2.10B
- Outstanding Shares: 20,898,000
- Beta: 1.39
- Net Margins: 8.51%
- Return on Equity: 9.98%
- Return on Assets: 5.56%
Companies Related to Ligand Pharmaceuticals:
- Debt-to-Equity Ratio: 0.09%
- Current Ratio: 0.62%
- Quick Ratio: 0.60%
What is Ligand Pharmaceuticals' stock symbol?
Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."
Where is Ligand Pharmaceuticals' stock going? Where will Ligand Pharmaceuticals' stock price be in 2017?
6 brokerages have issued 12 month price objectives for Ligand Pharmaceuticals' shares. Their forecasts range from $105.00 to $160.00. On average, they anticipate Ligand Pharmaceuticals' stock price to reach $136.86 in the next year.
When will Ligand Pharmaceuticals announce their earnings?
Ligand Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May, 2nd 2017.
Who owns Ligand Pharmaceuticals stock?
Ligand Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include William Blair Investment Management LLC (5.81%), Knott David M (4.78%), State Street Corp (4.06%), Cardinal Capital Management LLC CT (3.67%), FMR LLC (2.33%) and Russell Investments Group Ltd. (1.34%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, David M Knott, Jason Aryeh, John L Higgins, John W Kozarich, Matthew W Foehr, Melanie J Herman, Nishan M Desilva and Sunil Patel.
Who sold Ligand Pharmaceuticals stock? Who is selling Ligand Pharmaceuticals stock?
Ligand Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Columbia Wanger Asset Management LLC, Guggenheim Capital LLC, State Street Corp, AQR Capital Management LLC, JW Asset Management LLC, Paradigm Asset Management Co. LLC and Turner Investments LLC. Company insiders that have sold Ligand Pharmaceuticals stock in the last year include Jason Aryeh, John L Higgins, John W Kozarich, Matthew W Foehr and Melanie J Herman.
Who bought Ligand Pharmaceuticals stock? Who is buying Ligand Pharmaceuticals stock?
Ligand Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., William Blair Investment Management LLC, Cardinal Capital Management LLC CT, Janus Capital Management LLC, Osterweis Capital Management Inc., Gabelli Funds LLC, Employees Retirement System of Texas and RK Capital Management LLC.
How do I buy Ligand Pharmaceuticals stock?
Shares of Ligand Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Ligand Pharmaceuticals stock cost?
One share of Ligand Pharmaceuticals stock can currently be purchased for approximately $100.38.